UConn Health Launches CAR-T Cell Therapy Program for Blood Cancers
The program’s first patient has already begun T-cell collection; manufacturing takes several weeks then the modified cells will be infused.

Key Points
- UConn Health has launched a CAR-T cell therapy program at the Carole and Ray Neag Comprehensive Cancer Center, becoming one of two centers in Connecticut offering the treatment.
- CAR-T therapy uses a patient’s own genetically modified T cells to recognize and attack cancer cells.
- The program’s first patient has begun T-cell collection, with infusion scheduled after manufacturing is complete.
UConn Health has launched a CAR-T cell therapy program at the Carole and Ray Neag Comprehensive Cancer Center, making it the first program to bring the treatment to patients in the Hartford County area and joining Yale as one of only two centers in Connecticut offering it. The launch follows nearly two years of preparation involving clinical teams, nursing, pharmacy, laboratory services, information technology, finance, quality, and hospital leadership.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
Dr. Kapil Meleveedu, director of UConn Health’s Blood and Marrow Transplant and Cellular Therapy Program, says, “CAR-T cell therapy has been one of the most significant advances in the treatment of blood cancers over the past decade. Bringing it to UConn Health means more patients can access this highly specialized care closer to home.”
How the therapy works
Unlike traditional medications, CAR-T therapy uses a patient’s own immune cells to fight cancer. T cells, a type of white blood cell, are collected from the patient’s bloodstream and sent to a specialized manufacturing facility, where they are genetically modified to produce chimeric antigen receptors, or CARs, that enable them to recognize and attack specific cancer cells. The modified cells are multiplied and returned to UConn Health for infusion back into the patient. Because the cells can continue to grow and function inside the body, the therapy is sometimes described as a “living drug.”
“We are taking the patient’s own immune cells and training them to identify and attack the cancer,” Meleveedu says. “Once they are returned to the patient, these cells can act like an internal army that continues to search for its target.”
The FDA approved the first CAR-T therapy in 2017. The treatment is now approved for several blood cancers and may be an option for certain patients whose cancer has returned or has not responded to other therapies. Meleveedu says long-term data show that certain patients who once had few remaining treatment options are now achieving durable remissions, with some potentially cured of their disease.
“These are patients who, historically, may have had a life expectancy of only months because other treatments were no longer working,” Meleveedu says. “CAR-T therapy has given many of them a new opportunity and, in some cases, long-term survival. That is what makes this advancement so meaningful.”
Patients receiving CAR-T therapy are monitored closely because the treatment can produce serious side effects. One potential complication is cytokine release syndrome, an intense immune response that can cause fever, body aches, low blood pressure, or difficulty breathing. Some patients may also experience temporary neurological effects, such as confusion or difficulty finding words.
“Our first priority is always safety,” Meleveedu says. “We know these therapies can work. Our responsibility is to make sure we have the expertise, systems and support in place to guide patients through treatment as safely as possible.”
First patient and access
UConn Health already has its first patient moving through the CAR-T process, beginning with the collection of the patient’s T cells. Manufacturing typically takes several weeks, with the infusion scheduled after the modified cells are returned.
Until now, many patients seeking CAR-T therapy in central Connecticut and surrounding areas have had to travel farther from home. “Patients facing a serious blood cancer should not have to leave their community or travel long distances to receive this level of care,” Meleveedu says. “They can now come to UConn Health for a consultation, learn whether CAR-T may be appropriate for them and receive this highly specialized treatment from a team close to home.”
“This program is emblematic of UConn’s commitment to enabling access to top-notch, cutting edge cancer care for patients in the state of Connecticut,” says Dr. Margaret Callahan, Professor of Medicine and Chief of the Hematology and Oncology Division at UConn Health.
While CAR-T therapy was first developed for cancer, researchers are now studying whether the same technology could be used to treat autoimmune and neurological conditions. “This is more than a new treatment, it is a new technology that has the potential to transform how we approach many diseases,” Meleveedu says. “As an academic medical center, UConn Health is at the forefront of advances like this. Most importantly, it gives us another powerful way to help patients who urgently need new options.”
“As an academic medical center, UConn Health has a mission not only to treat cancer, but to innovate and advance cancer treatment, so that our patients today have better options than what was available in the past. Drs. Kapil Meleveedu and Swarup Kumar, along with their multidisciplinary teams have been tireless in working to advance the treatment options available for patients here at UConn,” Callahan says.
“Bringing CAR T-cell therapy to UConn Health has been a truly multidisciplinary effort,” Meleveedu says. “Our hospital leadership made this program a priority and provided the support and timely decisions that allowed us to launch ahead of schedule to meet a patient’s needs. Andrea Moran, BMT/cell therapy operational program director and our cell therapy team coordinated the many steps needed to prepare the program, with vital contributions from our nursing, pharmacy, lab, IT, finance, contracting, and Cancer Center teams. Their work has made it possible to offer this treatment to patients here.”
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
AbelZeta Receives FDA RMAT and Fast Track Designations for Anti-CD20/CD19 Bispecific CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma
Octane Biotech and Currus Biologics Automate CAR T-Cell Therapy Manufacturing
Cellares and GenomeFrontier Therapeutics Partnering on Automated Virus-Free CAR-T Program for Phase 1
Vyriad Begins Mayo Clinic CAR-T Phase 1 for Multiple Myeloma
FDA Clears Colorado University Anschutz’ CAR T-Cell Trial for Colorectal Cancer
University Hospital Tuebingen’s New Trial Tests CD19 CAR T-Cell Therapy for Autoimmune Diseases
Tikva Allocell Presents Preclinical Findings on Armored Allogeneic CD19 CAR T-Cell Therapy for Systemic Lupus Erythematosus
CellFiber Opens First International Subsidiary in Philadelphia to Support Cell and Gene Therapy Development







